Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease

• Status: Completed
• Trial end date: 2017-10-19
• Target enrollment: 0
• Participant gender: All

Summary

Er:YAG ablative fractional laser-assisted methyl aminolevulinate photodynamic therapy (AFL-PDT) has shown significantly higher efficacy and a lower recurrence rate at 12 months than methyl aminolevulinate photodynamic therapy (MAL-PDT) for treatment of Bowen's disease (BD). However, long-term follow up data are not available.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A University
• Treatments: Aminolevulinic Acid; EMLA; Lidocaine; Lidocaine, Prilocaine Drug Combination; Methyl 5-aminolevulinate; Prilocaine

Criteria

Inclusion Criteria:

• •Patients aged 18 years or more who diagnosed as bowen's disease

Exclusion Criteria:

• pregnancy or lactation

• active systemic infectious disease

• other inflammatory, infectious, or neoplastic skin diseases in the treated area

• allergy to MAL,other topical photosensitizers, or excipients of the cream

• history of photosensitivity

• use of immunosuppressive or photosensitizing drugs

• participation in any other investigational study in the preceding 30 days

• history or indicators of poor compliance

• Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria